Heart failure with preserved ejection fraction (HFpEF) is a clinical syn- drome characterized by impaired left ventricular (LV) relaxation, ele- vated LV filling pressures, fluid retention, and microvascular dysfunction. Described as the ‘single largest unmet need in cardiovascular medicine’, HFpEF represents 65% of new HF diagnoses and associates with a poor prognosis.
Tackling myocardial oxidative stress with empagliflozin: Are we big enough to fight heart failure with preserved ejection fraction? / Paneni, F.; Sciarretta, S.; Costantino, S.. - In: CARDIOVASCULAR RESEARCH. - ISSN 0008-6363. - 117:2(2021), pp. 343-345. [10.1093/cvr/cvaa196]
Tackling myocardial oxidative stress with empagliflozin: Are we big enough to fight heart failure with preserved ejection fraction?
Sciarretta S.;
2021
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a clinical syn- drome characterized by impaired left ventricular (LV) relaxation, ele- vated LV filling pressures, fluid retention, and microvascular dysfunction. Described as the ‘single largest unmet need in cardiovascular medicine’, HFpEF represents 65% of new HF diagnoses and associates with a poor prognosis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
